SCHEMBL5537449

SCHEMBL5537449

Cc1ccccc1-c1ncsc1CO[C]=O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.33
MAPK13 O15264 1/20 0.32
MAPK12 P53778 1/20 0.32
MAPK11 Q15759 1/20 0.32
MAPK14 Q16539 1/20 0.32
SLC6A3 Q01959 1/20 0.32
PIK3CD O00329 1/20 0.32
FFAR1 O14842 3/20 0.32
FFAR4 Q5NUL3 2/20 0.32
DPP4 P27487 1/20 0.32
LMNA P02545 2/20 0.31
KDM5A P29375 1/20 0.31
CTSA P10619 1/20 0.31
NOTUM Q6P988 1/20 0.31
PLA2G7 Q13093 1/20 0.30
NPC1 O15118 1/20 0.30
TP53 P04637 1/20 0.30
GAA P10253 1/20 0.30
MAPK1 P28482 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544619 0.83 MAPK14 (0.38) ADORA2AMAPK13MAPK12MAPK11MAPK14
SCHEMBL28015141 0.81 DPP4 (0.35) DPP4SMN1; SMN2
SCHEMBL5534779 0.80 FFAR4 (0.36) FFAR4DPP4NOTUMMAPK1
SCHEMBL5538359 0.80 FFAR4 (0.37) ADORA2ASLC6A3FFAR4
SCHEMBL5537646 0.78 NR1H2 (0.38)
SCHEMBL5543582 0.74 ALDH1A1 (0.47) SLC6A3LMNAMAPK1SMN1; SMN2MEN1
SCHEMBL5548160 0.73 MAPT (0.34) FFAR4NPC1RAB9AMEN1KMT2A
SCHEMBL5539400 0.72 FFAR1 (0.41) FFAR1LMNANPC1TP53GAA
SCHEMBL27729659 0.67 ADORA2A (0.37) ADORA2AMAPK13MAPK12MAPK11MAPK14
SCHEMBL5541839 0.65 KDM4E (0.30) LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ADORA2A 1954/4885MAPK13 1600/4885MAPK12 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.